---
freshness:
  last-reviewed: 2025-01-28
  data-year: 2025
  review-cycle: 12
  sections:
    - name: "Phase 1 Actions"
      data-year: 2025
    - name: "Phase 2 Actions"
      data-year: 2025
    - name: "Phase 3 Actions"
      data-year: 2025
    - name: "Success Metrics"
      data-year: 2025
notes:
  - Timelines assume Congressional action beginning in 2025-2026.
  - Phase durations are estimates; actual timelines depend on political conditions.
  - Budget estimates are in 2025 dollars.
  - Success metrics should be updated annually with latest available data.
sources:
  count: 12
  verified: 2025-01-28
  broken: 0
---

# The Opioid Crisis: Implementation Roadmap

## Overview

This roadmap outlines a three-phase implementation plan for the comprehensive opioid crisis response described in the Solutions analysis. The phases are designed to sequence interventions from highest-impact, most-feasible actions (Phase 1) through systemic reforms requiring longer timelines (Phase 3). All phases overlap; Phase 2 actions begin before Phase 1 is complete, and Phase 3 planning begins during Phase 2 implementation.

The roadmap is organized around the principle that reducing mortality is the immediate priority, expanding treatment capacity is the medium-term imperative, and systemic reform is the long-term goal.

---

## Phase 1: Emergency Response and Quick Wins (Months 1-18)

### Objective

Reduce overdose deaths by 15-20% through immediate deployment of life-saving interventions and removal of barriers to existing evidence-based treatments.

### Legislative Actions

| Action | Vehicle | Timeline | Lead |
|--------|---------|----------|------|
| Pass Comprehensive Opioid Response and Accountability Act | Standalone legislation or appropriations rider | Months 1-6 | Congress |
| Appropriate $3 billion for emergency naloxone distribution | Supplemental appropriation | Months 1-3 | Congress (Appropriations) |
| Mandate MAT in federal prisons and funded jails | Federal legislation + DOJ policy | Months 1-6 | Congress, DOJ |
| Authorize methadone reform (office-based prescribing pilot) | Federal legislation | Months 3-12 | Congress, SAMHSA |
| Codify permanent telehealth MAT authorization | Federal legislation | Months 1-6 | Congress, DEA |
| Fund State Opioid Response grants at $2.5 billion/year | Appropriations | Months 1-6 | Congress |
| Remove federal syringe purchase funding prohibition | Appropriations rider | Months 1-6 | Congress |

### Executive Actions

| Action | Authority | Timeline | Lead |
|--------|-----------|----------|------|
| Declare renewed public health emergency with funding activation | Public Health Service Act | Month 1 | HHS Secretary |
| Issue SAMHSA guidance on settlement fund best practices | Existing authority | Months 1-3 | SAMHSA |
| Expand methadone take-home flexibility (permanent) | 42 CFR Part 8 rulemaking | Months 1-12 | SAMHSA |
| Issue DEA guidance supporting buprenorphine prescribing | Existing authority | Months 1-3 | DEA |
| Negotiate bulk naloxone pricing for federal programs | Federal procurement authority | Months 3-6 | HHS |
| Launch national naloxone awareness campaign | Existing communications budget | Months 1-3 | ONDCP, CDC |
| Direct CDC to update overdose surveillance for near-real-time | Existing authority, reallocation | Months 1-12 | CDC |

### State-Level Actions

| Action | Model | Timeline | Lead |
|--------|-------|----------|------|
| Establish independent settlement fund oversight boards | Model legislation | Months 1-12 | State legislatures |
| Enact naloxone standing orders in remaining jurisdictions | Policy adoption | Months 1-6 | State health officers |
| Remove syringe services program restrictions | State legislation | Months 1-12 | State legislatures |
| Enact Good Samaritan law protections in remaining states | State legislation | Months 1-12 | State legislatures |
| Mandate MAT in state-funded correctional facilities | State legislation or executive order | Months 6-18 | Governors, legislatures |

### Phase 1 Resource Requirements

| Resource | Estimated Cost | Funding Source |
|----------|---------------|----------------|
| Emergency naloxone distribution | $3 billion (one-time) | Federal supplemental appropriation |
| State Opioid Response grants (annual) | $2.5 billion | Federal appropriation |
| Telehealth infrastructure support | $200 million | Federal grants |
| Settlement fund oversight technical assistance | $50 million | Federal appropriation |
| Public awareness campaigns | $100 million | Federal appropriation |
| **Phase 1 Total (first 18 months)** | **~$6 billion (federal)** | **Mixed** |

---

## Phase 2: System Building and Treatment Expansion (Months 12-48)

### Objective

Increase the MAT treatment rate from 22% to 40% of the OUD population, establish sustainable treatment and harm reduction infrastructure, and implement settlement fund programs at scale.

### Legislative Actions

| Action | Vehicle | Timeline | Lead |
|--------|---------|----------|------|
| Pass MAT Access Expansion Act (full methadone reform) | Federal legislation | Months 12-24 | Congress |
| Pass Naloxone for All Act (universal access program) | Federal legislation | Months 12-18 | Congress |
| Authorize safe consumption site pilot program (amend 21 U.S.C. 856) | Federal legislation | Months 18-36 | Congress |
| Mandate addiction medicine in medical school accreditation | Federal education/HHS legislation | Months 12-24 | Congress, AAMC |
| Establish addiction treatment workforce loan forgiveness | Federal legislation | Months 12-24 | Congress |
| Require Medicaid MAT coverage in all states (including non-expansion) | Federal legislation or CMS waiver policy | Months 12-36 | Congress, CMS |
| Restore DEA suspicious order suspension authority | Repeal/amend 2016 Act | Months 12-24 | Congress |
| Pass FDA post-market surveillance reform for opioids | Federal legislation | Months 18-36 | Congress |

### Implementation Actions

| Action | Lead Agency | Timeline | Key Milestones |
|--------|------------|----------|----------------|
| Deploy national real-time overdose surveillance | CDC | Months 12-36 | System design (M12), pilot (M24), national launch (M36) |
| Establish 500 new MAT prescriber sites in treatment deserts | SAMHSA, HRSA | Months 12-36 | 200 by M24, 500 by M36 |
| Fund 100 new opioid treatment programs in underserved areas | SAMHSA | Months 12-48 | 40 by M24, 100 by M48 |
| Train 10,000 new peer recovery support specialists | SAMHSA | Months 12-36 | 3,000 by M18, 10,000 by M36 |
| Implement settlement fund evidence-based programs | States, local govts. | Months 12-48 | Programs operational in 40+ states by M24 |
| Launch prescriber support "warm line" in all states | SAMHSA PCSS | Months 12-24 | 25 states by M18, all states by M24 |
| Establish fentanyl drug checking pilot programs in 20 cities | SAMHSA, local orgs. | Months 12-30 | 10 cities by M18, 20 by M30 |
| Deploy mobile MAT units in 200 rural counties | HRSA, SAMHSA | Months 18-48 | 80 by M24, 200 by M48 |

### State-Level Actions

| Action | Model | Timeline | Lead |
|--------|-------|----------|------|
| All states establish PDMP interstate data sharing | Interstate compact | Months 12-36 | State legislatures, PDMP administrators |
| Non-expansion states establish OUD Medicaid coverage | State legislation or 1115 waivers | Months 12-48 | State legislatures, CMS |
| All correctional facilities (state and local) provide MAT | State mandates, SAMHSA funding | Months 12-48 | States, counties |
| Establish state-level addiction treatment quality standards | State regulation | Months 18-36 | State health agencies |
| Expand harm reduction legal frameworks (SSPs, drug checking) | State legislation | Months 12-36 | State legislatures |

### Phase 2 Resource Requirements

| Resource | Estimated Annual Cost | Funding Source |
|----------|----------------------|----------------|
| MAT expansion grants (new sites, OTPs, mobile units) | $3 billion/year | Federal appropriation |
| Workforce development (training, loan forgiveness) | $2 billion/year | Federal appropriation |
| National surveillance system | $500 million (total build) | Federal appropriation |
| Harm reduction expansion (SSPs, drug checking, SCS pilots) | $1 billion/year | Federal/state |
| Treatment quality and data systems | $500 million/year | Federal appropriation |
| Prevention programs | $1.5 billion/year | Federal/state |
| **Phase 2 Annual Total** | **~$8.5 billion/year (federal)** | **Mixed** |

---

## Phase 3: Systemic Reform and Sustained Response (Months 36-120)

### Objective

Increase the MAT treatment rate to 60%+ of the OUD population, reduce annual opioid overdose deaths by 50% from peak levels, establish permanent treatment infrastructure, and implement structural reforms that prevent future pharmaceutical-driven epidemics.

### Legislative Actions

| Action | Vehicle | Timeline | Lead |
|--------|---------|----------|------|
| Establish permanent addiction treatment entitlement | Federal legislation (major healthcare reform) | Months 36-72 | Congress |
| Reform FDA user fee structure to reduce industry dependency | Federal legislation | Months 36-60 | Congress |
| Implement pharmaceutical industry revolving door restrictions | Federal legislation | Months 36-48 | Congress |
| Establish national drug checking and alert system | Federal legislation | Months 36-60 | Congress |
| Reform Controlled Substances Act methadone provisions | Federal legislation | Months 36-60 | Congress |
| Create permanent opioid crisis response fund (mandatory spending) | Federal legislation | Months 48-72 | Congress |

### Systemic Reforms

| Reform | Scope | Timeline | Key Milestones |
|--------|-------|----------|----------------|
| Integrate addiction medicine into primary care standard | National | Months 36-84 | AAMC standards by M48, workforce transformation by M84 |
| Achieve MAT treatment rate of 60%+ | National | Months 36-120 | 40% by M48, 50% by M72, 60% by M120 |
| Full integration of behavioral health and primary care | National | Months 48-120 | Payment reform by M60, delivery reform ongoing |
| Establish community-based prevention in all high-risk areas | National | Months 36-84 | Evidence-based programs in 80% of target communities by M84 |
| Complete settlement fund distribution and evaluation | National | Months 36-180 | Most funds distributed by M180 (15-year schedules) |
| International precursor control framework | International | Months 36-120 | Bilateral agreements by M48, multilateral framework by M120 |

### Phase 3 Resource Requirements

| Resource | Estimated Annual Cost | Funding Source |
|----------|----------------------|----------------|
| Permanent treatment infrastructure (ongoing) | $5-8 billion/year | Federal mandatory spending |
| Workforce maintenance and expansion | $2-3 billion/year | Federal/state |
| Prevention and community investment | $2-4 billion/year | Federal/state |
| Research and innovation | $1-2 billion/year | NIDA, federal research budget |
| Surveillance and data systems (ongoing) | $300 million/year | Federal |
| **Phase 3 Annual Total** | **~$10-17 billion/year** | **Mixed** |

---

## Success Metrics

### Mortality Metrics

| Metric | Baseline (2023) | Phase 1 Target (18 mo.) | Phase 2 Target (48 mo.) | Phase 3 Target (120 mo.) |
|--------|-----------------|------------------------|------------------------|--------------------------|
| Annual opioid overdose deaths | ~81,000 | ~68,000 (-16%) | ~55,000 (-32%) | ~40,000 (-51%) |
| Annual synthetic opioid deaths | ~74,500 | ~63,000 (-15%) | ~50,000 (-33%) | ~35,000 (-53%) |
| Overdose death rate per 100,000 | 24.7 | 20.5 | 16.5 | 11.8 |
| Racial disparity ratio (highest/lowest group) | 9.8:1 | 8.0:1 | 6.0:1 | 4.0:1 |

### Treatment Metrics

| Metric | Baseline (2023) | Phase 1 Target | Phase 2 Target | Phase 3 Target |
|--------|-----------------|----------------|----------------|----------------|
| MAT treatment rate (% of OUD pop.) | 22% | 28% | 40% | 60% |
| Buprenorphine prescribers actively treating | ~70,000 | 100,000 | 150,000 | 200,000 |
| OTP capacity (number of programs) | ~1,900 | 2,100 | 2,500 | 3,000 |
| Counties with no MAT access | ~500 | 300 | 100 | 0 |
| Treatment retention at 6 months | ~45% | 50% | 55% | 65% |

### Harm Reduction Metrics

| Metric | Baseline (2023) | Phase 1 Target | Phase 2 Target | Phase 3 Target |
|--------|-----------------|----------------|----------------|----------------|
| Naloxone kits distributed annually | 3.2 million | 8 million | 15 million | 20 million |
| States with comprehensive SSP authorization | ~40 | 45 | 50 | 50 |
| Annual naloxone reversals (documented) | ~53,000 | 100,000 | 200,000 | 300,000 |
| Drug checking service availability (cities) | ~15 | 30 | 50 | 100 |

### Prescribing Metrics

| Metric | Baseline (2023) | Phase 1 Target | Phase 2 Target | Phase 3 Target |
|--------|-----------------|----------------|----------------|----------------|
| Opioid prescribing rate per 100 persons | 43.3 | 40.0 | 35.0 | 30.0 |
| High-dose prescriptions (>90 MME) | 5.2% | 4.0% | 3.0% | 2.0% |
| PDMP consultation rate before prescribing | ~70% | 90% | 98% | 99% |
| New persistent opioid use after surgery | ~6% | 4.5% | 3.0% | 2.0% |

### Accountability Metrics

| Metric | Baseline (2024) | Phase 1 Target | Phase 2 Target | Phase 3 Target |
|--------|-----------------|----------------|----------------|----------------|
| States with independent settlement oversight | ~20 | 35 | 45 | 50 |
| Settlement funds directed to evidence-based uses | ~60% | 75% | 85% | 90% |
| Settlement fund expenditure transparency score | Low | Medium | High | High |

---

## Risk Analysis

### Implementation Risks

| Risk | Probability | Impact | Mitigation |
|------|------------|--------|------------|
| Political opposition blocks legislation | High | High | Pursue executive and state-level actions simultaneously; build bipartisan coalitions |
| Settlement funds diverted to general budgets | Medium-High | High | Independent oversight boards, public transparency, media attention |
| Workforce shortages limit treatment expansion | High | High | Aggressive loan forgiveness, training programs, telehealth expansion |
| New synthetic opioid (nitazenes) escalates crisis | Medium | Very High | Invest in surveillance, drug checking, flexible response capacity |
| Provider reluctance limits buprenorphine uptake | High | Medium | Mentorship programs, practice support, institutional mandates |
| Fentanyl supply increases faster than response | Medium | High | Demand-reduction focus; supply interdiction as complement, not primary strategy |
| Political backlash against harm reduction | Medium | Medium | Evidence communication, community engagement, gradual implementation |
| Recession reduces government funding capacity | Medium | High | Establish mandatory spending streams; demonstrate economic case for investment |

### External Dependencies

| Dependency | Status | Contingency |
|------------|--------|-------------|
| Congressional action on major legislation | Uncertain | Executive actions, state-level implementation, administrative reform |
| International cooperation on precursor control | Slow progress | Unilateral sanctions, technology-based interdiction, demand reduction emphasis |
| State-level political will for harm reduction | Variable | Federal incentives and conditions, peer state modeling, evidence campaigns |
| Insurance industry cooperation on MAT coverage | Improving | Federal mandates, parity enforcement, litigation |
| Provider workforce pipeline | Insufficient | Telehealth, task-shifting, loan forgiveness, expanded scope of practice |

---

## Governance Structure

### Federal Coordination

- **Lead Agency**: ONDCP (policy coordination), SAMHSA (treatment and prevention), CDC (surveillance), DEA (enforcement)
- **Interagency Task Force**: Standing interagency body with quarterly reporting and annual strategy updates
- **Congressional Oversight**: Bipartisan opioid caucus with regular oversight hearings and annual progress report

### State Coordination

- **State Opioid Response Plans**: Every state develops a comprehensive plan with measurable targets
- **Regional Cooperation**: Multi-state compacts for PDMP data sharing, workforce development, and settlement fund coordination
- **Best Practice Sharing**: SAMHSA-funded learning collaboratives for state and local implementation

### Community Engagement

- **Local Advisory Boards**: Community-level advisory bodies including people with lived experience, families, providers, and law enforcement
- **Participatory Budgeting**: Community input into local settlement fund allocation decisions
- **Accountability Mechanisms**: Public dashboards tracking local outcomes against state and national targets

---

## Document Navigation

- Previous: [Solutions](07-solutions.md)
- Next: [Resources](09-resources.md)
- Up: [Overview](01-overview.md)
